Cambridge celebrated the first ever LGBTSTEM Day on 5 July – recognising all those who work in science, technology, engineering and medicine and who identify as lesbian, gay, bisexual, transgender and other minority gender identities and sexual orientations.
Nanotechnology is creating new opportunities for fighting disease – from delivering drugs in smart packaging to nanobots powered by the world’s tiniest engines.
A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known human enzyme, which may have implications for treating respiratory diseases such as asthma.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
A University of Cambridge cancer research laboratory which uses imaging technologies to measure key biologic changes within growing tumours has announced a three-year oncology research collaboration with Medimmune.